Last reviewed: June 8, 2026
Last updated: June 8, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
The combination of GLP-1 receptor agonists like semaglutide with testosterone replacement therapy is gaining attention in precision medicine circles, particularly for patients seeking comprehensive metabolic optimization. Research suggests these therapies may address different physiological mechanisms—one targeting appetite signaling and the other supporting muscle protein synthesis. Understanding how they interact requires examining both individual mechanisms and the emerging clinical evidence.
How Semaglutide and Testosterone Work on Separate Metabolic Pathways
Semaglutide activates glucagon-like peptide-1 receptors in the hypothalamus and gastrointestinal tract, reducing hunger signals and slowing gastric emptying. This mechanism promotes caloric deficit by decreasing appetite drive rather than forcing restriction through willpower alone. The medication also improves insulin sensitivity and stabilizes blood glucose patterns, supporting metabolic efficiency during weight loss.
Testosterone operates through androgen receptors distributed across muscle tissue, bone, liver, and the central nervous system. In individuals with low testosterone, replacement therapy restores the hormonal signal that directs the body to build and maintain lean muscle mass. Unlike semaglutide's appetite-suppressing action, testosterone's primary role involves preserving muscle during caloric deficit and supporting metabolic rate through increased muscle density.
The Synergistic Potential: Muscle Preservation During Weight Loss
One of the most compelling reasons to consider combination therapy is the muscle-sparing effect when both therapies are aligned. Semaglutide creates the caloric deficit needed for weight loss, but prolonged caloric restriction can trigger muscle catabolism if protein intake and hormonal support are insufficient. Testosterone replacement signals the body to prioritize muscle retention by enhancing protein synthesis and reducing the catabolic stress response during energy deficit.
Studies on GLP-1 therapy alone show that approximately 25–40% of weight loss may come from lean muscle tissue if not carefully managed. Adding testosterone support may shift this ratio, preserving muscle while maximizing fat loss. This distinction matters clinically: preserved muscle maintains resting metabolic rate, improves body composition aesthetics, and supports long-term weight stability by preventing the metabolic adaptation that often follows muscle loss.
Clinical Considerations for Safe Combination Therapy
Combining semaglutide with testosterone requires baseline evaluation and ongoing monitoring because both therapies affect metabolic parameters. Patients should have testosterone levels measured before starting therapy; testosterone replacement is appropriate only for individuals with clinically low levels (typically below 300 ng/dL), not as a performance-enhancing agent. Similarly, semaglutide requires screening for personal or family history of medullary thyroid carcinoma and assessment of kidney function.
When both therapies are used together, clinicians typically monitor hemoglobin A1C, lipid panels, liver function, and hematocrit levels more frequently during the first three months. Semaglutide can lower blood glucose significantly, requiring adjustment of other diabetes medications if present. Testosterone may increase hematocrit, necessitating periodic blood work to ensure values remain in safe ranges. PlexusDx coordinates with prescribing providers to ensure comprehensive monitoring protocols align with personalized treatment goals.
Personalized Optimization With Genetic Insights
Not all patients respond identically to semaglutide, and genetic variation plays a measurable role in therapy outcomes. The PlexusDx Precision Peptide Genetic Test identifies variants in key genes—including GLP1R (rs6923761), MC4R (rs17782313), FTO (rs9939609), and GIPR (rs1800437)—that influence GLP-1 sensitivity and metabolic predisposition. Understanding your genetic peptide profile allows clinicians to anticipate which dose ranges and medication combinations may yield optimal results.
Similarly, genetic factors influence testosterone receptor function and metabolism. By mapping 14 metabolic pathways across 49 peptides, the Precision Peptide test provides a foundation for matching therapy intensity to individual biology. Patients with lower GLP-1 receptor signaling capacity may benefit from dual-compound therapy like GLP-Squared, which combines semaglutide and tirzepatide to activate both GLP-1 and GIP pathways. This personalized approach reduces trial-and-error adjustments and accelerates the path to therapeutic benefit.
PlexusDx GLP-Squared: Dual Compound Support for Enhanced Results
GLP-Squared represents PlexusDx's dual-compound innovation, combining semaglutide and tirzepatide in a single injection formulation. Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, offering broader metabolic pathway engagement than semaglutide alone. For patients pursuing combination therapy with testosterone, GLP-Squared injection starting at $249/month provides an efficient foundation—your dose may need to go up, but your price won't.
The convenience of GLP-Squared reduces injection frequency and simplifies medication management, supporting adherence during the months-long optimization period. Compounded from licensed 503A pharmacies, GLP-Squared is available to all 50 states without insurance requirements, making it accessible for patients building a comprehensive metabolic strategy. When paired with testosterone therapy managed by your primary care provider, GLP-Squared creates a streamlined protocol focused on fat loss, muscle retention, and sustainable metabolic health.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Glp Squared starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Is combining semaglutide and testosterone safe?
When prescribed by qualified clinicians with appropriate baseline testing and monitoring, combination therapy is generally well-tolerated. Both medications require periodic lab work to track glucose, lipids, liver function, and blood counts. PlexusDx recommends coordinating care between your primary care provider (managing testosterone) and your GLP-1 prescriber to ensure comprehensive oversight and medication interactions are minimized.
Can semaglutide and testosterone really preserve muscle during weight loss?
Clinical evidence suggests testosterone supports muscle protein synthesis while semaglutide creates the caloric deficit, potentially reducing muscle catabolism. Studies show testosterone replacement improves lean mass retention in men with low baseline levels, and combining it with GLP-1 therapy may amplify this effect. However, adequate protein intake (0.8–1.0 grams per pound of body weight) and resistance training remain essential components of muscle preservation.
How much does GLP-Squared cost at PlexusDx?
PlexusDx GLP-Squared injection starts at $249 per month across all commitment tiers, with no flat per-compound pricing increases. The medication is compounded in licensed 503A pharmacies, requires no insurance, and is HSA/FSA eligible. Add the Precision Peptide Genetic Test for $99 after your first month to personalize your therapy based on your unique peptide pathway profile.
What side effects should I expect when combining these therapies?
Semaglutide commonly causes gastrointestinal effects (nausea, constipation) that typically diminish over weeks. Testosterone may increase libido, energy, and mood but can raise hematocrit and acne risk in some individuals. Serious adverse events are rare with proper screening and monitoring, though semaglutide carries a boxed warning regarding medullary thyroid carcinoma risk (avoid if personal or family history is present).
How does the PlexusDx Precision Peptide Genetic Test help with combination therapy?
The test identifies variants in GLP1R, MC4R, FTO, and GIPR genes that predict individual GLP-1 responsiveness and metabolic predisposition. This insight helps your clinician determine whether dual-compound therapy like GLP-Squared, higher starting doses, or adjunctive approaches may accelerate your results. Genetic data also informs testosterone dosing optimization in some cases, though testosterone pharmacogenomics is distinct from peptide pathway testing.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How to Get Ozempic or Semaglutide in Nashville
What is GLP-1 Microdosing and How Can It Support Your Weight Loss Journey?